Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Revenue Growth On Track For A 10.6% CAGR Through 2030
The market size for pharmaceutical contract development and manufacturing organizations (CDMOs) specializing in formulations has experienced significant expansion recently. This market is projected to expand from $54.73 billion in 2025 to $60.7 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.9%. Historically, this growth can be ascribed to factors such as the restricted supply of specialized peptide API manufacturers, a dependency on internal peptide production, an expanding pipeline of peptide therapeutics, stricter regulatory compliance demands, and the implementation of fundamental chemical synthesis techniques.
The market size for pharmaceutical contract development and manufacturing organizations (CDMOs) for formulations is projected to experience substantial growth over the next few years. It is expected to expand to $90.76 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 10.6%. This projected growth can be ascribed to several factors, including advancements in custom peptide synthesis technologies, the expansion of commercial-scale GMP manufacturing, increased outsourcing to CROs and SMEs, the development of lifecycle management and process optimization strategies, and the rising demand for clinical and preclinical peptide API manufacturing. Significant trends for the forecast period include the increasing outsourcing of peptide API manufacturing to specialized contract manufacturers, a surge in GMP-grade production for both clinical and commercial supplies, a heightened need for custom peptide synthesis and purification services, the expansion of peptide therapeutics pipelines across pharmaceutical companies, and a strong focus on process optimization and lifecycle management for peptide APIs.
Get A Free Sample Report With In-Depth Market Insights:
Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Growth Drivers: What’s Behind The Acceleration?
The expansion in drug development and manufacturing endeavors is anticipated to boost the growth of the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market in the coming years. These activities encompass the heightened efforts of pharmaceutical and biopharmaceutical firms to research, create, and produce new medications. Their escalation is mainly driven by the increasing worldwide need for innovative and effective therapies, compelling companies to broaden their development pipelines and accelerate manufacturing schedules. A pharmaceutical CDMO plays a crucial role in assisting drug development by formulating and refining dosage forms, conducting stability tests, and guaranteeing adherence to regulations. Furthermore, it oversees the scaling-up and production processes, which facilitates quicker and more cost-effective product introductions. Illustratively, data from June 2023, provided by the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based trade association representing the pharmaceutical industry in Europe, indicated that the total pharmaceutical production in Europe reached $422,803 million (€390,000 million) in 2023, an increase from $393,857 million (€363,300 million) in 2022. Consequently, the expanding scope of drug development and manufacturing activities is a significant catalyst for the growth of the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market.
Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Segmentation And Category Overview
The pharmaceutical contract development and manufacturing organization (cdmo) for formulations market covered in this report is segmented –
1) By Dosage Form: Oral Solids, Oral Liquids, Injectables, Topicals, Inhalation Products, Transdermal And Patches, Other Dosage Forms
2) By Therapeutic Area: Oncology, Cardiology, Central Nervous System, Gastroenterology, Infectious Diseases, Endocrinology
3) By End-User: Pharmaceutical Companies, Biopharmaceutical Companies, Other End-Users
Subsegments:
1) By Oral Solids: Tablets, Capsules, Granules, Powders, Modified-Release Formulations
2) By Oral Liquids: Syrups, Suspensions, Solutions, Emulsions, Elixirs
3) By Injectables: Vials, Ampoules, Prefilled Syringes, Lyophilized Injections, Injectable Emulsions
4) By Topicals: Creams, Ointments, Gels, Lotions, Foams,
5) By Inhalation Products: Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs), Nebulizer Solutions, Nasal Sprays, Inhalation Capsules
6) By Transdermal And Patches: Matrix Patches, Reservoir Patches, Drug-In-Adhesive Patches, Microneedle Patches, Iontophoretic Patches
7) By Other Dosage Forms: Suppositories, Ophthalmic Preparations, Buccal Tablets, Sublingual Tablets, Implants
Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Trends: What’s Defining The Industry’s Next Phase?
Leading companies within the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market are concentrating on creating advanced solutions, such as biologic formulation platforms, with the goal of enhancing drug stability and expediting the market entry for complex biologic therapies. Biologic formulation platforms are specialized systems engineered to produce stable and efficient formulations of biologic drugs. These platforms meticulously adjust elements like pH, excipients, and delivery methods to improve stability, bioavailability, and safety throughout the entire product lifecycle. For instance, in June 2025, WuXi Biologics, a China-based contract research, development, and manufacturing organization, introduced WuXiHigh 2.0, which is a next-generation high-concentration formulation platform. This sophisticated platform enables biologic formulations to achieve protein concentrations of up to 230 mg/mL, surpassing the current Food and Drug Administration-approved maximum of 200 mg/mL. Concurrently, it reduces viscosity by up to 90% through proprietary excipient blends and high-throughput instrumentation. The platform is designed to address key challenges in developing high-concentration biologics, particularly viscosity and aggregation, and aims to enhance injection efficiency, patient compliance, and manufacturing outcomes across both clinical and commercial stages.
Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the pharmaceutical contract development and manufacturing organization (cdmo) for formulations market are Thermo Fisher Scientific Inc., Lonza Group, Catalent Inc., WuXi Biologics, Samsung Biologics, Recipharm AB, Siegfried Holding AG, Evonik Industries AG, Almac Group, Aenova Group, Piramal Pharma Limited, Cambrex, Jubilant Pharmova Limited, CordenPharma, Altasciences, Hovione, Aurigene Pharmaceutical Services Ltd., DPT Laboratories Ltd., CARBOGEN AMCIS, Biopharma Group, LGM Pharma, Aarti Pharmalabs Limited.
View The Full Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Report:
Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Regional Split: Which Areas Are Fueling Growth?
Asia-Pacific was the largest region in the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmaceutical contract development and manufacturing organization (cdmo) for formulations market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
